Trial Profile

Olmesartan medoxomil/amlodipine versus olmesartan medoxomil/hydrochlorothiazide in hypertensive patients with metabolic syndrom: the OLAS study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil/amlodipine (Primary) ; Olmesartan medoxomil/hydrochlorothiazide (Primary) ; Olmesartan medoxomil
Indications Hypertension; Metabolic syndrome
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Acronyms OLAS

Most Recent Events

13 May 2012 Status changed from not stated to completed.
29 Apr 2012 Results presented at the 22nd European Meeting on Hypertension.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com